Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands

CEO Christopher J. Moreau said the company is thrilled to initiate its clinical stroke research program with this study as “preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor which is an important part of the brain’s recovery process after an injury like a stroke.”

The trial, to be conducted at the …

Full story available on Benzinga.com